Quelicin

A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Quelicin is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. .
[PubChem].

Quelicin - Pharmacology:

The mechanism of action of Quelicin involves what appears to be a "persistent" depolarization of the neuromuscular junction. This depolarization is caused by Quelicin mimicking the effect of acetylcholine but without being rapidly hydrolysed by acetylcholinesterase. This depolarization leads to desensitization.

Quelicin mini report

Quelicin NDA
NDA - A product marketed under an approved New Drug Application
Quelicin INTRAMUSCULAR; INTRAVENOUS
INTRAMUSCULAR; INTRAVENOUS
Quelicin INJECTION, SOLUTION
INJECTION, SOLUTION
Quelicin HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Quelicin global name
Succinylcholine Chloride
Start - Stop data
START DATA:
1953-May-01
Start - Stop data
STOP DATA
not occurred

Quelicin Interactions

Drugs which may enhance the neuromuscular blocking action of succinylcholine include: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, b-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, diethylether, isoflurane, desflurane, metoclopramide, and terbutaline. The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase.

If other neuromuscular blocking agents are to be used during the same procedure, the possibility of a synergistic or antagonistic effect should be considered.

 

Quelicin Contraindications

Quelicin is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest. The risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. The risk is dependent on the extent and location of the injury. The precise time of onset and the duration of the risk period are not known.

Generic name, Overdose, Half Life Quelicin, Food Interactions, Chemical, etc..

Quelicin see also FDA report

Brand Names containing Succinylcholine